Neoadjuvant Chemoradiotherapy (ncrt) Combined with Sequential Tislelizumab for Resectable Esophageal Squamous Cell Carcinoma (ESCC): Preliminary Results of a Single-Arm, Open-Label Phase Ib Trial (CRIS).
Journal of Clinical Oncology（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要